Stock listing

Frankfurt:2TK Eledon Pharmaceuticals, Inc. Aktie

German listing (Frankfurt) of Eledon Pharmaceuticals, Inc. · home listing NASDAQ:ELDN

Follow Eledon Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Share price · FWB:2TK

€1.83 EUR +0.07 (+4.0%)

Close on Nov 19, 2026

Past year +66.7% · daily closes, Nov 19, 2025 – Nov 6, 2026, adjusted for splits
Day range
€1.83 – €1.83 EURNov 19, 2026
Market cap
€148.7M EURAt the close on Nov 19, 2026 · price × 81.26M shares outstanding
52-week range
€1.16 – €3.62 EURLowest and highest trades, Nov 20, 2025 – Nov 19, 2026
Traded on an average day
€883 EURMedian day 0 shares · 45 days with no trades · last 3 months, Aug 19, 2026 – Nov 6, 2026
Eledon Pharmaceuticals, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:ELDN · Home$1.78 USD-0.25 (-12.3%)1,292,761$1.87$2.00$1.76$2.03Close on Nov 20, 2026
Frankfurt:2TK€1.83 EUR+0.07 (+4.0%)—€1.83€1.83€1.83€1.76Close on Nov 19, 2026

Daily closes

Last 3 months, Aug 19, 2026 – Nov 6, 2026 · FWB:2TK · EUR, adjusted for splits

DayCloseChange%OpenHighLowVolume
€2.139-0.168-7.3%€2.139€2.139€2.1390
€2.307+0.047+2.1%€2.307€2.307€2.307168
€2.26+0.004+0.2%€2.26€2.26€2.26168
€2.256-0.166-6.9%€2.256€2.256€2.2560
€2.422-0.171-6.6%€2.422€2.422€2.4220
€2.593+0.21+8.8%€2.593€2.593€2.5931,000
€2.383+0.292+14.0%€2.383€2.383€2.38311,780
€2.091+0.164+8.5%€2.091€2.091€2.091892
€1.927-0.072-3.6%€1.927€1.927€1.9270
€1.999+0.001+0.1%€1.999€1.999€1.9990
€1.998+0.069+3.6%€1.998€1.998€1.9980
€1.929-0.04-2.0%€1.929€1.929€1.9290
€1.969+0.102+5.5%€1.969€1.969€1.9690
€1.867+0.015+0.8%€1.867€1.867€1.8670
€1.852-0.062-3.2%€1.852€1.852€1.8520
€1.914-0.016-0.8%€1.961€1.961€1.910
€1.93-0.092-4.5%€1.93€1.93€1.930
€2.022-0.093-4.4%€2.022€2.022€2.0220
€2.115-0.042-1.9%€2.115€2.115€2.1150
€2.157+0.055+2.6%€2.157€2.157€2.1570
€2.102-0.012-0.6%€2.102€2.102€2.1022,000
€2.114-0.01-0.5%€2.114€2.114€2.114800
€2.124-0.065-3.0%€2.124€2.124€2.1240
€2.189+0.03+1.4%€2.189€2.189€2.1890
€2.159+0.051+2.4%€2.159€2.159€2.1590
€2.108-0.069-3.2%€2.108€2.108€2.1080
€2.177+0.037+1.7%€2.177€2.177€2.1770
€2.14-0.115-5.1%€2.14€2.14€2.140
€2.255-0.024-1.1%€2.255€2.255€2.2550
€2.279-0.09-3.8%€2.279€2.279€2.2790
€2.369+0.039+1.7%€2.313€2.392€2.3113,086
€2.33-0.125-5.1%€2.328€2.362€2.322800
€2.455+0.171+7.5%€2.455€2.455€2.4550
€2.284-0.07-3.0%€2.284€2.284€2.2840
€2.354+0.122+5.5%€2.367€2.373€2.353500
€2.232-0.046-2.0%€2.232€2.232€2.232166
€2.2780.000.0%€2.278€2.278€2.2780
€2.278-0.051-2.2%€2.278€2.278€2.2780
€2.329+0.011+0.5%€2.329€2.329€2.3290
€2.318-0.025-1.1%€2.318€2.318€2.3180
€2.343-0.025-1.1%€2.343€2.343€2.343500
€2.368-0.208-8.1%€2.368€2.368€2.3680
€2.576+0.067+2.7%€2.463€2.591€2.44150
€2.5090.000.0%€2.509€2.509€2.5090
€2.509+0.049+2.0%€2.509€2.509€2.5090
€2.46-0.052-2.1%€2.46€2.46€2.460
€2.512-0.014-0.6%€2.512€2.512€2.5120
€2.526+0.041+1.6%€2.526€2.526€2.5260
€2.485-0.198-7.4%€2.485€2.485€2.4850
€2.683-0.094-3.4%€2.683€2.683€2.6830
€2.777-0.024-0.9%€2.777€2.777€2.7770
€2.801-0.067-2.3%€2.801€2.801€2.8010
€2.868+0.034+1.2%€2.868€2.868€2.8680
€2.834-0.018-0.6%€2.834€2.834€2.8340
€2.852-0.053-1.8%€2.852€2.852€2.8520
€2.905-0.044-1.5%€2.905€2.905€2.9050
€2.949-0.069-2.3%€2.949€2.949€2.9490
€3.018+0.037+1.2%€3.018€3.018€3.0180

Splits

2 splits since 2017 · FWB:2TK · every price before a split is adjusted for it

DayRatioWhat
1-for-18Consolidation
1-for-9Consolidation
Ticker
Frankfurt:2TK
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Frankfurt
Currency
EUR

What changed lately

Latest news

All Eledon Pharmaceuticals, Inc. news

Eledon Pharmaceuticals, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
20 in the last 12 months · 97 in all · newest Nov 12, 2026 · oldest 2021
Calls
10 calls with a replay · 10 with a transcript · latest May 9, 2024
Decks
7 decks · latest September 2026

Where Eledon Pharmaceuticals, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:ELDN · Home listingNASDAQUnited StatesUSD
BOATS:ELDNBOATSUnited StatesUSD
Lang & Schwarz:A2QL00Lang & SchwarzGermanyEUR
LS Exchange:A2QL00LS ExchangeGermanyEUR
Tradegate:2TKTradegateGermanyEUR
Dusseldorf:2TKDusseldorfGermanyEUR
Frankfurt:2TK · This pageFrankfurtGermanyEUR
Munich:2TKMunichGermanyEUR
Stuttgart:2TKStuttgartGermanyEUR

Valuation

Price/book 4.9× against a median of 1.6×: 9th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$80.67M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
4.9×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.95

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Eledon Pharmaceuticals, Inc. · NASDAQ:ELDNUS$150.3MUS$80.67Mn/an/an/a4.9×n/a0.0×1.95
BioVersys AG · SIX:BIOVUS$154.1MUS$97.45Mn/a102×n/a2.9×n/a0.5×n/a
InflaRx N.V. · NASDAQ:IFRXUS$153.3MUS$135.7Mn/a4,215×n/a19.5×n/a0.0×1.61
Polaris Group · TWSE:6550US$153.0MUS$154.8Mn/a75.1×n/a1.1×n/a0.5×n/a
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H · HKEX:1541US$152.0MUS$64.59Mn/a2.9×n/a1.6×−141.7%0.6×n/a
Saniona AB · OMXSTO:SANIONUS$151.6MUS$104.0M8.4×2.5×5.2×2.8×43.2%0.0×n/a
Palisade Bio, Inc. · NASDAQ:PALIUS$150.6MUS$36.96Mn/a73.9×n/a1.3×n/a0.0×1.41
Veraxa Biotech AG · NASDAQ:VRXAUS$147.1MUS$145.1Mn/a5,202×n/an/an/an/a1.11
ProQR Therapeutics N.V. · NASDAQ:PRQRUS$146.8MUS$49.73Mn/a2.2×n/a2.0×−210.7%0.2×1.73
ALX Oncology Holdings Inc. · NASDAQ:ALXOUS$146.6MUS$9.57Mn/an/an/a1.2×n/a0.1×0.68
Bicycle Therapeutics PLC · NASDAQ:BCYCUS$146.1M−US$323.8Mn/a−3.9×n/a0.3×−169.8%0.0×1.59
Median of the othersUS$151.1MUS$81.02M8.4×73.9×5.2×1.6×−155.7%0.1×1.50

Forecasts

6 strong buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
9.00 USD · Analysts' mean
EPS, year to Dec 2026
-0.93 · 4 analysts

Team and board

Officers

OfficerRole
David-Alexandre C. GrosCEO and Director
Paul LittleChief Financial Officer
Steven PerrinPresident and Chief Scientific Officer
Bryan SmithGeneral Counsel
Carlos CandidoVice President, Cell Therapy Operations
John HerbergerVice President, Technical Operations
Marcela Laurito-TrammellVice President, Clinical Development – Transplantation
Marina EscuderoVice President, and Head of Clinical Operations
Sepideh HabibiVice President, and Head of Safety & Pharmacovigilance
Yulan LiVice President, Biometrics
David HovlandChief Regulatory Officer

Board

DirectorRole
Keith A. KatkinChairman of the Board of Directors
Allan KirkDirector
David-Alexandre C. GrosCEO and Director
James RobinsonDirector
Jan HillsonDirector
John S. McBrideDirector
June LeeDirector

Events

Results days

QuarterResultsShare move
Q3 2026Nov 12, 2026 · After close−10.6%
Q2 2026Aug 13, 2026 · After close−4.3%
Q1 2026May 7, 2026+2.1%
Q4 2025Mar 19, 2026 · After close+1.1%
Q3 2025Nov 14, 2025 · After close−8.0%
Q2 2025Aug 14, 2025 · After close+1.1%
Q1 2025May 14, 2025 · After close+2.1%
Q4 2024Mar 26, 2025 · Before open−2.9%
Q3 2024Nov 12, 2024 · After close−11.4%
Q2 2024Aug 19, 2024 · After close+3.5%
All 20 quarters
QuarterResultsShare move
Q1 2024May 13, 2024 · After close+6.8%
Q4 2023Mar 28, 2024 · After close−3.4%
Q3 2023Nov 9, 2023 · After close+0.9%
Q2 2023Aug 10, 2023 · Before open+1.6%
Q1 2023May 11, 2023 · After close−13.0%
Q4 2022Mar 30, 2023 · After close−6.0%
Q3 2022Nov 14, 2022 · After close−3.6%
Q2 2022Aug 11, 2022 · After close−1.1%
Q1 2022May 12, 2022 · After close+9.9%
Q4 2021Mar 24, 2022 · After close+4.0%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (September 2026)Investor deck33 slidesSeptember 2026
Technical Presentation (November 2025)Technical32 slidesNov 7, 2025
Investor Day (July 2025)Investor day114 slidesJul 9, 2025
Technical Presentation (November 2023)Technical15 slidesNov 2, 2023
Investor Presentation (January 2023)Investor deck25 slidesJan 9, 2023
Technical Presentation (May 2022)Technical21 slidesMay 31, 2022
Technical PresentationTechnical18 slides

Open Decks

Financings

RaiseDate
Public offering of common stock and pre-funded warrants
Closed: US$57.5M raised · US$1.65 a share · Leerink Partners +2
Dealers: Leerink Partners (co-lead), Cantor (co-lead), LifeSci Capital (co-lead)
Use of proceeds: Advance tegoprubart programs in kidney transplantation, islet cell transplantation and xenotransplantation
Nov 14, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Went public as Tokai Pharmaceuticals Inc. Priced at US$15.00 a share on Sep 16, 2014.

Price
US$15.00 a share
Shares offered
6,480,000 shares of common stock
Offering size
US$97.2 million
Underwriters' option
Up to 972,000 more shares
Underwriters
BMO Capital Markets, Stifel, William Blair, Janney Montgomery Scott · In the order on the cover
Shares delivered
On or about Sep 22, 2014

Steps

StepWhen
Draft sent to the SEC in confidenceMay 2, 2014
Filed publiclyAug 11, 2014
Amended onceSep 2, 2014
Shares registered with an exchangeSep 12, 2014
Declared effective by the SECSep 16, 2014
Final prospectus, with the priceSep 18, 2014

Open IPO · From the cover of the final prospectus (424B4) filed Sep 18, 2014

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue0000120.0K120.0K0000
Cost of revenue359.0K374.0K373.0K195.0K183.0K182.0K11.0K22.0K35.0K
Gross profit-359.0K-374.0K-373.0K120.0K-183.0K-182.0K-11.0K-22.0K-35.0K
Research and development66.3M52.0M30.3M27.1M23.7M6.13M8.13M6.82M2.02M3.19M
Selling, general and administrative17.0M18.6M12.7M12.7M13.1M10.1M6.06M7.24M11.1M13.1M
Operating income-83.3M-70.6M-43.0M-88.4M-36.9M-18.5M-16.1M-14.1M-13.1M-5.13M
Depreciation and amortization313.0K359.0K374.0K373.0K195.0K5.00K9.00K11.0K22.0K35.0K
EBITDA-82.9M-70.2M-42.6M-88.1M-36.7M-18.5M-16.0M-14.0M-13.1M-5.09M
Interest expense462.0K202.0K9.66M0000
Income before tax-45.6M-35.8M-116.5M-88.0M-36.9M-23.2M-16.0M-14.1M-13.1M-5.66M
Income tax35.0K431.0K00-2.35M-404.0K1.87M-5.00K0
Net income-45.6M-36.2M-116.5M-88.0M-34.5M-22.8M-16.0M-14.1M-13.1M-5.66M
Earnings per share, basic-0.52-0.66-4.73-6.16-2.33-15.72-24.42-1.56-2.30-2.46
Earnings per share, diluted-0.52-0.66-4.73-6.16-2.33-15.72-24.42-1.56-2.30-2.46

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents22.8M20.5M4.61M56.4M84.8M114.2M8.79M13.0M17.2M1.10M
Short-term investments110.5M119.6M46.5M04.17M
Receivables514.0K110.0K245.0K594.0K
Inventory1.29M881.0K
Current assets135.7M143.7M56.1M59.5M88.3M115.6M9.97M14.3M19.0M1.15M
Property, plant and equipment768.0K138.0K5.00K14.0K25.0K31.0K
Goodwill0048.6M48.6M01.87M1.87M
Total assets169.0M177.4M89.1M92.8M170.5M197.2M10.9M17.0M20.9M1.20M
Accounts payable3.63M5.83M967.0K2.20M1.81M1.37M329.0K689.0K418.0K338.0K
Current liabilities18.3M11.6M3.90M6.47M4.40M2.48M1.32M2.53M1.44M3.90M
Total debt00000003.45M
Total liabilities32.2M59.3M81.9M8.61M6.55M6.59M1.47M2.53M1.44M3.90M
Shareholders' equity81.1M62.4M-48.5M23.8M164.0M190.6M9.46M14.5M19.5M-2.70M
Shares outstanding75.4M59.8M24.2M13.8M14.3M15.2M720.4K9.42M7.11M394.3K

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-62.3M-47.3M-39.5M-28.4M-28.9M-15.2M-13.9M-11.9M-14.9M-4.92M
Capital spending000000000-9.00K
Free cash flow-62.3M-47.3M-39.5M-28.4M-28.9M-15.2M-13.9M-11.9M-14.9M-4.93M
Cash from investing10.8M-70.3M-45.3M11.0M11.0M11.0M23.3M1.00K
Cash from financing53.8M133.5M33.0M33.0M-449.0K109.6M9.68M7.56M7.87M2.93M
Dividends paid-25.0K
Share buybacks-25
Change in cash2.26M15.9M-51.8M-28.4M-29.4M105.4M-4.18M-4.33M16.2M-1.99M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 12, 2026Quarterly reportSEC
8-K · Current reportNov 12, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 30, 2026Big-stake noticeSEC
S-8 · Registration statement for employee plansSep 4, 2026Offer documentSEC
10-Q · Quarterly reportAug 13, 2026Quarterly reportSEC
8-K · Current reportAug 13, 2026ResultsSEC
4 · Change in ownershipAug 4, 2026Insider tradeSEC
4 · Change in ownershipAug 4, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeJul 31, 2026Big-stake noticeSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportJun 22, 2026Meeting outcomeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 13, 2026Quarterly reportSEC
8-K · Current reportMay 13, 2026ResultsSEC
EFFECT · Notice that a registration is effectiveMay 12, 2026Other filingsSEC
CORRESP · Letter to the SECMay 7, 2026Other filingsSEC
UPLOAD · Letter from the SECMay 7, 2026Other filingsSEC
S-3 · Registration statementMay 1, 2026Offer documentSEC
DEFA14A · Additional proxy materialApr 30, 2026Meeting noticeSEC
ARS · Annual report to shareholdersApr 30, 2026Annual reportSEC
DEF 14A · Proxy statementApr 30, 2026Meeting noticeSEC
SCHEDULE 13G · Big-stake noticeApr 27, 2026Big-stake noticeSEC
PRE 14A · Preliminary proxy statementApr 20, 2026Meeting noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 26, 2026Big-stake noticeSEC
10-K · Annual reportMar 19, 2026Annual reportSEC
8-K · Current reportMar 19, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 21, 2026Big-stake noticeSEC
4 · Change in ownershipJan 16, 2026Insider tradeSEC
4 · Change in ownershipJan 16, 2026Insider tradeSEC
4 · Change in ownershipJan 16, 2026Insider tradeSEC
4 · Change in ownershipJan 16, 2026Insider tradeSEC
4 · Change in ownershipJan 16, 2026Insider tradeSEC
4 · Change in ownershipJan 16, 2026Insider tradeSEC
8-K · Current reportJan 2, 2026FinancingSEC
SCHEDULE 13G · Big-stake noticeNov 24, 2025Big-stake noticeSEC
8-K · Current reportNov 14, 2025ResultsSEC
10-Q · Quarterly reportNov 14, 2025Quarterly reportSEC
8-K · Current reportNov 12, 2025Material contractSEC
424B5 · ProspectusNov 12, 2025Offer documentSEC
424B5 · ProspectusNov 12, 2025Offer documentSEC
8-K · Current reportNov 6, 2025ResultsSEC
10-Q · Quarterly reportAug 14, 2025Quarterly reportSEC
10-Q/A · Quarterly report, amendedAug 14, 2025Quarterly reportSEC
10-K/A · Annual report, amendedAug 14, 2025Annual reportSEC
8-K · Current reportAug 14, 2025ResultsSEC
8-K · Current reportAug 6, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeJul 29, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJul 17, 2025Big-stake noticeSEC
8-K · Current reportJun 12, 2025Meeting outcomeSEC
10-Q · Quarterly reportMay 14, 2025Quarterly reportSEC
8-K · Current reportMay 14, 2025ResultsSEC
ARS · Annual report to shareholdersApr 29, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 29, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 29, 2025Meeting noticeSEC
PRE 14A · Preliminary proxy statementApr 14, 2025Meeting noticeSEC
8-K/A · Current report, amendedApr 14, 2025Current reportSEC
8-K · Current reportApr 7, 2025Current reportSEC
10-K · Annual reportMar 20, 2025Annual reportSEC
8-K · Current reportMar 20, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
4 · Change in ownershipJan 13, 2025Insider tradeSEC
4 · Change in ownershipJan 13, 2025Insider tradeSEC
4 · Change in ownershipJan 13, 2025Insider tradeSEC
4 · Change in ownershipJan 13, 2025Insider tradeSEC
4 · Change in ownershipJan 13, 2025Insider tradeSEC
4 · Change in ownershipJan 13, 2025Insider tradeSEC
4 · Change in ownershipJan 13, 2025Insider tradeSEC
4 · Change in ownershipJan 13, 2025Insider tradeSEC
4 · Change in ownershipJan 13, 2025Insider tradeSEC
4 · Change in ownershipJan 13, 2025Insider tradeSEC
8-K · Current reportDec 20, 2024Management or board changeSEC
4 · Change in ownershipNov 22, 2024Insider tradeSEC
4 · Change in ownershipNov 22, 2024Insider tradeSEC
4 · Change in ownershipNov 22, 2024Insider tradeSEC
4 · Change in ownershipNov 22, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 12, 2024Quarterly reportSEC
8-K · Current reportNov 12, 2024ResultsSEC
SC 13G · Big-stake noticeNov 5, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 5, 2024Big-stake noticeSEC
4 · Change in ownershipOct 31, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedOct 31, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedOct 31, 2024Big-stake noticeSEC
424B5 · ProspectusOct 30, 2024Offer documentSEC
424B5 · ProspectusOct 30, 2024Offer documentSEC
8-K · Current reportOct 29, 2024Material contractSEC
8-K · Current reportOct 29, 2024Current reportSEC
EFFECT · Notice that a registration is effectiveOct 3, 2024Other filingsSEC
8-K · Current reportOct 1, 2024FinancingSEC
CORRESP · Letter to the SECSep 30, 2024Other filingsSEC
UPLOAD · Letter from the SECSep 26, 2024Other filingsSEC
8-K · Current reportSep 20, 2024Material contractSEC
S-3 · Registration statementSep 20, 2024Offer documentSEC
10-Q · Quarterly reportAug 19, 2024Quarterly reportSEC
10-Q/A · Quarterly report, amendedAug 19, 2024Quarterly reportSEC
10-K/A · Annual report, amendedAug 19, 2024Annual reportSEC
8-K · Current reportAug 14, 2024ResultsSEC
NT 10-Q · Late filing noticeAug 14, 2024Explanation requestSEC
8-K · Current reportJul 12, 2024Current reportSEC
8-K · Current reportJul 10, 2024FinancingSEC
8-K · Current reportJul 10, 2024Management or board changeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
424B3 · ProspectusJun 6, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveJun 6, 2024Other filingsSEC
CORRESP · Letter to the SECJun 3, 2024Other filingsSEC
UPLOAD · Letter from the SECMay 30, 2024Other filingsSEC
ARS · Annual report to shareholdersMay 30, 2024Annual reportSEC
DEFA14A · Additional proxy materialMay 30, 2024Meeting noticeSEC
DEF 14A · Proxy statementMay 30, 2024Meeting noticeSEC
S-3 · Registration statementMay 24, 2024Offer documentSEC
DMay 22, 2024Other filingsSEC
10-Q · Quarterly reportMay 15, 2024Quarterly reportSEC
4 · Change in ownershipMay 13, 2024Insider tradeSEC
8-K · Current reportMay 13, 2024ResultsSEC
8-K · Current reportMay 7, 2024Material contractSEC
10-K/A · Annual report, amendedApr 26, 2024Annual reportSEC
10-K · Annual reportMar 28, 2024Annual reportSEC
8-K · Current reportMar 28, 2024ResultsSEC
SC 13G · Big-stake noticeFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 9, 2023Quarterly reportSEC
8-K · Current reportNov 9, 2023ResultsSEC
8-K · Current reportNov 2, 2023Current reportSEC
4 · Change in ownershipOct 3, 2023Insider tradeSEC
4 · Change in ownershipOct 3, 2023Insider tradeSEC
3 · Initial statement of ownershipOct 2, 2023Insider tradeSEC
3 · Initial statement of ownershipOct 2, 2023Insider tradeSEC
8-K · Current reportOct 2, 2023Management or board changeSEC
8-K · Current reportSep 20, 2023Management or board changeSEC
8-K · Current reportSep 13, 2023Management or board changeSEC
S-8 · Registration statement for employee plansAug 10, 2023Offer documentSEC
10-Q · Quarterly reportAug 10, 2023Quarterly reportSEC
8-K · Current reportAug 10, 2023ResultsSEC
8-K · Current reportJun 21, 2023Management or board changeSEC
424B3 · ProspectusJun 8, 2023Offer documentSEC
EFFECT · Notice that a registration is effectiveJun 5, 2023Other filingsSEC
CORRESP · Letter to the SECMay 31, 2023Other filingsSEC
UPLOAD · Letter from the SECMay 24, 2023Other filingsSEC
DMay 22, 2023Other filingsSEC
S-3 · Registration statementMay 18, 2023Offer documentSEC
10-Q · Quarterly reportMay 11, 2023Quarterly reportSEC
8-K · Current reportMay 11, 2023ResultsSEC
4 · Change in ownershipMay 9, 2023Insider tradeSEC
4 · Change in ownershipMay 2, 2023Insider tradeSEC
4 · Change in ownershipMay 2, 2023Insider tradeSEC
4 · Change in ownershipMay 2, 2023Insider tradeSEC
4 · Change in ownershipMay 2, 2023Insider tradeSEC
4 · Change in ownershipMay 2, 2023Insider tradeSEC
4 · Change in ownershipMay 2, 2023Insider tradeSEC
4 · Change in ownershipMay 2, 2023Insider tradeSEC
4 · Change in ownershipMay 2, 2023Insider tradeSEC
4 · Change in ownershipMay 2, 2023Insider tradeSEC
4 · Change in ownershipMay 2, 2023Insider tradeSEC
DEF 14A · Proxy statementMay 1, 2023Meeting noticeSEC
ARS · Annual report to shareholdersMay 1, 2023Annual reportSEC
DEFA14A · Additional proxy materialMay 1, 2023Meeting noticeSEC
8-K · Current reportMay 1, 2023Material contractSEC
10-K · Annual reportMar 30, 2023Annual reportSEC
8-K · Current reportMar 30, 2023ResultsSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2023Big-stake noticeSEC
4 · Change in ownershipFeb 2, 2023Insider tradeSEC
4 · Change in ownershipFeb 2, 2023Insider tradeSEC
4 · Change in ownershipFeb 2, 2023Insider tradeSEC
4 · Change in ownershipFeb 2, 2023Insider tradeSEC
4 · Change in ownershipFeb 2, 2023Insider tradeSEC
4 · Change in ownershipFeb 2, 2023Insider tradeSEC
4 · Change in ownershipFeb 2, 2023Insider tradeSEC
4 · Change in ownershipFeb 2, 2023Insider tradeSEC
4 · Change in ownershipFeb 2, 2023Insider tradeSEC
4 · Change in ownershipFeb 2, 2023Insider tradeSEC
8-K · Current reportJan 9, 2023Current reportSEC
4 · Change in ownershipNov 23, 2022Insider tradeSEC
10-Q · Quarterly reportNov 14, 2022Quarterly reportSEC
8-K · Current reportNov 14, 2022ResultsSEC
10-Q · Quarterly reportAug 11, 2022Quarterly reportSEC
8-K · Current reportAug 11, 2022ResultsSEC
8-K · Current reportJun 22, 2022Meeting outcomeSEC
8-K · Current reportMay 31, 2022Current reportSEC
10-Q · Quarterly reportMay 12, 2022Quarterly reportSEC
8-K · Current reportMay 12, 2022ResultsSEC
DEFA14A · Additional proxy materialApr 28, 2022Meeting noticeSEC
DEF 14A · Proxy statementApr 28, 2022Meeting noticeSEC
10-K · Annual reportMar 24, 2022Annual reportSEC
8-K · Current reportMar 24, 2022ResultsSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2022Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 11, 2022Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 10, 2022Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 9, 2022Big-stake noticeSEC
4 · Change in ownershipFeb 2, 2022Insider tradeSEC
4 · Change in ownershipFeb 2, 2022Insider tradeSEC
4 · Change in ownershipFeb 2, 2022Insider tradeSEC
4 · Change in ownershipFeb 2, 2022Insider tradeSEC
4 · Change in ownershipFeb 2, 2022Insider tradeSEC

This page holds 200 of 617 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Eledon Pharmaceuticals, Inc.’s releases · as of Nov 10, 2026

Common shares
84,459,713
Fully diluted
84,459,713

Fully diluted

LineSharesAs of
Common shares84,459,713Nov 10, 2026

Share count over time

CountShares
Nov 10, 202684,459,713

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
BlackRock6.64M7.9%US$16.8MSep 30, 2026
Bvf Inc6.29M7.5%US$15.9MSep 30, 2026
Vanguard4.57M5.4%US$11.6MSep 30, 2026
Defilade Capital Management, L.P.3.53M4.2%US$8.92MSep 30, 2026
Goldman Sachs2.56M3.0%US$6.48MSep 30, 2026
Geode Capital1.98M2.3%US$5.01MSep 30, 2026
Ensign Peak Advisors, Inc1.76M2.1%US$4.44MSep 30, 2026
Catalio Capital Management, LP1.64M1.9%US$4.14MSep 30, 2026
State Street1.61M1.9%US$4.09MSep 30, 2026
Sphera Funds Management LTD.1.39M1.6%US$3.52MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Zimmer Partners, LP1.2M1.4%US$3.04MSep 30, 2026
AWM Investment Company, Inc.1.1M1.3%US$2.78MSep 30, 2026
Millennium790K0.94%US$2MSep 30, 2026
ADAR1 Capital Management, LLC653K0.77%US$1.65MSep 30, 2026
22nw, LP636K0.75%US$1.61MSep 30, 2026
Northern Trust631K0.75%US$1.6MSep 30, 2026
Blue Owl Capital Holdings LP567K0.67%US$1.43MSep 30, 2026
Renaissance Technologies557K0.66%US$1.41MSep 30, 2026
UBS533K0.63%US$1.35MSep 30, 2026
CM Management, LLC525K0.62%US$1.33MSep 30, 2026
Dimensional512K0.61%US$1.29MSep 30, 2026
Jacobs Levy Equity Management, Inc485K0.57%US$1.23MSep 30, 2026
BIT Capital GmbH427K0.51%US$1.08MSep 30, 2026
Brevan Howard Capital Management LP381K0.45%US$965KSep 30, 2026
Triumph Capital Management317K0.37%US$801KSep 30, 2026
Bank of America307K0.36%US$778KSep 30, 2026
Susquehanna296K0.35%US$748KSep 30, 2026
Qube Research & Technologies Ltd271K0.32%US$686KSep 30, 2026
Morgan Stanley251K0.30%US$635KSep 30, 2026
Schwab247K0.29%US$626KSep 30, 2026
Nuveen224K0.27%US$567KSep 30, 2026
BNY159K0.19%US$402KSep 30, 2026
Russell Investments Group, Ltd.128K0.15%US$324KSep 30, 2026
LPL Financial LLC122K0.14%US$309KSep 30, 2026
Fidelity95,1100.11%US$241KSep 30, 2026
Daytona Street Capital LLC91,6660.11%US$231KSep 30, 2026
Rhumbline Advisers87,9880.10%US$223KSep 30, 2026
Prodigy Asset Management LLC86,7030.10%US$219KSep 30, 2026
AQR Capital Management LLC76,2150.09%US$193KSep 30, 2026
Raymond James Financial Inc76,1940.09%US$193KSep 30, 2026
Farmers & Merchants Investments Inc74,1230.09%US$188KSep 30, 2026
Rockefeller Capital Management L.P.72,6660.09%US$184KSep 30, 2026
Public Employees Retirement System Of Ohio68,0650.08%US$172KSep 30, 2026
DWS67,1700.08%US$170KSep 30, 2026
T. Rowe Price63,9840.08%US$162KSep 30, 2026
Invesco58,2370.07%US$147KSep 30, 2026
PW Nova Financial Services LLC58,0410.07%US$147KSep 30, 2026
Point72 Asset Management, L.P.53,2470.06%US$135KSep 30, 2026
Ingalls & Snyder LLC51,8490.06%US$131KSep 30, 2026
Simplex Trading, LLC46,8660.06%US$119KSep 30, 2026

This page holds 50 of 148 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund2.48M2.9%US$9.78MJun 30, 2026
iShares Russell 2000 ETF2.04M2.4%US$8.03MJun 30, 2026
Vanguard Extended Market Index Fund855K1.0%US$3.37MJun 30, 2026
Fidelity Small Cap Index Fund839K0.99%US$2.84MJul 31, 2026
iShares Russell 2000 Growth ETF723K0.86%US$2.85MJun 30, 2026
Fidelity Extended Market Index Fund389K0.46%US$1.48MMay 31, 2026
Vanguard Russell 2000 Index Fund384K0.45%US$1.46MMay 31, 2026
Goldman Sachs Small Cap Equity Insights Fund312K0.37%US$1.05MJul 31, 2026
Goldman Sachs Small Cap Value Insights Fund286K0.34%US$967KJul 31, 2026
iShares Micro-Cap ETF255K0.30%US$1.01MJun 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Dimensional U.S. Small Cap ETF197K0.23%US$666KJul 31, 2026
Schwab Small-Cap Index Fund187K0.22%US$633KJul 31, 2026
Fidelity Total Market Index Fund142K0.17%US$540KMay 31, 2026
Master Small Cap Index Series135K0.16%US$532KJun 30, 2026
Goldman Sachs Small Cap Growth Insights Fund130K0.15%US$438KJul 31, 2026
Fidelity Series Total Market Index Fund111K0.13%US$425KMay 31, 2026
Nuveen Small Cap Blend Index Fund103K0.12%US$347KJul 31, 2026
U.S. Micro Cap Portfolio92,1560.11%US$311KJul 31, 2026
EQ/2000 Managed Volatility Portfolio85,2000.10%US$336KJun 30, 2026
Goldman Sachs Variable Insurance Trust Small Cap Equity Insights Fund81,4090.10%US$321KJun 30, 2026
NVIT GS Small Cap Equity Insights Fund81,1030.10%US$320KJun 30, 2026
Nuveen Equity Index Fund79,3070.09%US$268KJul 31, 2026
Fidelity Small Cap Growth Index Fund72,1070.09%US$284KJun 30, 2026
Schwab Total Stock Market Index Fund59,9870.07%US$203KJul 31, 2026
Fidelity Nasdaq Composite Index Fund57,4450.07%US$219KMay 31, 2026
LVIP State Street Small-Cap Index Fund56,6000.07%US$223KJun 30, 2026
U.S. Small Cap Portfolio54,8360.06%US$185KJul 31, 2026
Vanguard Russell 2000 Value Index Fund53,9690.06%US$206KMay 31, 2026
Dimensional U.S. Core Equity 2 ETF45,6990.05%US$154KJul 31, 2026
Vanguard Balanced Index Fund43,5640.05%US$172KJun 30, 2026
Small Cap Index Fund39,7490.05%US$157KJun 30, 2026
Avantis U.S. Small Cap Equity ETF39,6300.05%US$151KMay 31, 2026
Fidelity ZERO Total Market Index Fund38,5930.05%US$130KJul 31, 2026
Global X Russell 2000 ETF36,7890.04%US$124KJul 31, 2026
Vanguard Institutional Total Stock Market Index Fund35,8630.04%US$141KJun 30, 2026
PACE Small/Medium Co Growth Equity Investments33,8000.04%US$114KJul 31, 2026
Bridge Builder Small/Mid Cap Value Fund33,0070.04%US$130KJun 30, 2026
Small Cap Index Fund30,9050.04%US$118KMay 31, 2026
Goldman Sachs Absolute Return Tracker Fund30,6760.04%US$121KJun 30, 2026
Fidelity ZERO Extended Market Index Fund26,6790.03%US$90,175Jul 31, 2026
Diversified Equity Alpha Master Portfolio25,7780.03%US$102KJun 30, 2026
State Street Small/Mid Cap Equity Index Portfolio25,5000.03%US$100KJun 30, 2026
MetLife Russell 2000 Index Portfolio23,2500.03%US$91,605Jun 30, 2026
Small-Cap Index Portfolio22,0710.03%US$86,960Jun 30, 2026
AVIP BlackRock Advantage Small Cap Growth Portfolio20,2970.02%US$79,970Jun 30, 2026
U.S. Core Equity 1 Portfolio17,6660.02%US$59,711Jul 31, 2026
ATM Small Cap Managed Volatility Portfolio17,4030.02%US$68,568Jun 30, 2026
1290 VT Micro Cap Portfolio17,2030.02%US$67,780Jun 30, 2026
Small Cap Index Trust16,7690.02%US$66,070Jun 30, 2026
EQ/AB Small Cap Growth Portfolio16,2000.02%US$63,828Jun 30, 2026

This page holds 50 of 103 holders. Open Shareholders

Big stakes

StakeStakeSharesDateFiling
BVF PARTNERS L P/IL9.99%8.66MSep 30, 2026Schedule 13G
BlackRock, Inc.5.80%4.38MMar 31, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Gary A. Lyons
Other companies: Travere Therapeutics, Inc. (Director · Since at least Oct 8, 2014); Neurocrine Biosciences, Inc. (Director · Since at least May 25, 2010); Brickell Biotech Inc (Director · Feb 14, 2020 – May 17, 2022 · Past); Humanigen Inc (Director · Aug 10, 2012 – Jul 10, 2015 · Past); NeurogesX Inc (Director · Apr 27, 2011 – Jun 7, 2012 · Past); Rigel Pharmaceuticals, Inc. (Director · May 28, 2010 – May 26, 2023 · Past); Vical Incorporated (Director · May 25, 2010 – May 23, 2018 · Past); Facet Biotech Corp (Director · Apr 20, 2010 – Apr 21, 2010 · Past)
Director · May 10, 2017 – May 1, 2023 · Past
Timothy J Barberich
Other companies: TScan Therapeutics, Inc. (Director · Jul 15, 2021 – Dec 18, 2023 · Past); Korro Bio, Inc. (Director · Oct 2, 2019 – Aug 17, 2022 · Past); Rocket Pharmaceuticals, Inc. (Director · Sep 28, 2016 – Jun 20, 2017 · Past); Verastem, Inc. (Director · Mar 10, 2014 – Jun 28, 2021 · Past); HeartWare International Inc (Director · Apr 29, 2008 – Aug 23, 2016 · Past); Biosphere Medical Inc (Director · May 10, 2006 – Sep 10, 2010 · Past); Sepracor Inc (Director · Mar 16, 2006 – Oct 20, 2009 · Past)
Director · Sep 16, 2014 – Jun 15, 2016 · Past
Keith A. Katkin
Other companies: Emergent BioSolutions Inc. (Independent Director · Since at least Apr 1, 2022); Syndax Pharmaceuticals, Inc. (Director · Since at least Mar 29, 2017); Urovant Sciences Ltd (PEO;CEO/Urovant Sciences, Inc., Director · Sep 26, 2018 – Feb 19, 2020 · Past); Rigel Pharmaceuticals, Inc. (Director · Jun 29, 2015 – May 19, 2021 · Past); Carbylan Therapeutics Inc (Director · Apr 8, 2015 – Aug 3, 2015 · Past); Avanir Pharmaceuticals Inc (President and CEO, Director · May 15, 2013 – Dec 15, 2014 · Past)
Chairman of the Board of Directors · Since at least May 10, 2017
James A Robinson Jr
Other companies: UroGen Pharma Ltd. (Director · Since at least Jul 25, 2023); Urovant Sciences Ltd (PEO;CEO/Urovant Sciences, Inc., Director · Mar 1, 2019 – Mar 29, 2021 · Past); Neos Therapeutics Inc (Director · Jan 29, 2019 – Mar 19, 2021 · Past); Alkermes plc (President & COO,Alkermes, Inc. · Mar 5, 2018 – Apr 4, 2019 · Past)
Director · Since at least Oct 1, 2023
Christine Ocampo
Other companies: Urovant Sciences Ltd (PAO; CAO/Urovant Sciences,Inc. · Sep 26, 2018 – Mar 29, 2021 · Past); Avanir Pharmaceuticals Inc (Vice President, Finance · Aug 11, 2010 – Dec 16, 2014 · Past)
See Remarks · May 10, 2017 – May 24, 2017 · Past
David-Alexandre C. Gros
Other companies: Neurocrine Biosciences, Inc. (President & COO · Jan 9, 2017 – Feb 6, 2017 · Past); Alnylam Pharmaceuticals, Inc. (SVP, Chief Business Officer · Jun 8, 2015 – Dec 20, 2016 · Past)
CEO and Director · Since at least Sep 9, 2020
Lee Kalowski
Other companies: Q32 Bio Inc. (PRESIDENT & CHIEF FINANCIAL OFFICER · Since at least Mar 25, 2024); Bicycle Therapeutics PLC (President and CFO · May 22, 2019 – Apr 3, 2023 · Past)
Chief Financial Officer · Sep 16, 2014 – Dec 15, 2015 · Past
Bryan Smith
Other companies: Urovant Sciences Ltd (GC/Urovant Sciences, Inc. · Sep 26, 2018 – Mar 29, 2021 · Past)
General Counsel · Since at least Apr 19, 2021
Catherine C Turkel
Other companies: Lexaria Bioscience Corp. (Director · Sep 2, 2022 – Aug 12, 2024 · Past)
President · May 20, 2019 – Mar 19, 2020 · Past
Gerald E Quirk
Other companies: Syros Pharmaceuticals, Inc. (Chief Legal & Compliance Offic · Sep 26, 2016 – Nov 19, 2024 · Past)
General Counsel, Executive VP · May 26, 2015 – Dec 15, 2015 · Past
All 27 people
PersonSeat
Jon Kuwahara
Other companies: Emmaus Life Sciences, Inc. (Director · Oct 1, 2024 – Oct 1, 2024 · Past)
See Remarks · May 20, 2019 – Sep 11, 2020 · Past
June Lee
Other companies: Tenaya Therapeutics, Inc. (Board Member · Since at least Oct 18, 2024)
Director · Since at least Jan 10, 2025
Stephen Buckley Jr
Other companies: Enanta Pharmaceuticals, Inc. (Director · Mar 20, 2013 – Feb 28, 2019 · Past)
Director · Jan 8, 2015 – Jun 15, 2016 · Past
Allan KirkDirector · Since at least Jul 17, 2025
Carlos CandidoVice President, Cell Therapy Operations · Since at least Nov 4, 2026
David HovlandChief Regulatory Officer · Since at least Nov 4, 2026
James RobinsonDirector · Since at least Nov 5, 2026
Jan HillsonDirector · Since at least Jan 10, 2026
John HerbergerVice President, Technical Operations · Since at least Nov 4, 2026
John S. McBrideDirector · Since at least Feb 1, 2022
Marcela Laurito-TrammellVice President, Clinical Development – Transplantation · Since at least Nov 4, 2026
Marina EscuderoVice President, and Head of Clinical Operations · Since at least Nov 4, 2026
Paul LittleChief Financial Officer · Since at least Nov 4, 2026
Sepideh HabibiVice President, and Head of Safety & Pharmacovigilance · Since at least Nov 4, 2026
Steven PerrinPresident, Director · Since at least Jul 31, 2026
Steven PerrinPresident and Chief Scientific Officer · Since at least Mar 4, 2026
Yulan LiVice President, Biometrics · Since at least Nov 4, 2026

Open People

Log in to ask 6ix AI your own questions about Eledon Pharmaceuticals, Inc.